## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A biocompatible hydrogel-forming tissue-bonding adhesive composition, the composition comprising:

at least one block copolymer polyol, wherein each hydroxyl of said block copolymer polyol is terminated with a low molecular weight polyisocyanate selected from toluene diisocyanate and isophorone diisocyanate, said terminated block copolymer polyol being liquid and water-soluble;

and wherein said block copolymer polyol is trifunctional and is formed from a reaction between a polyethylene/polypropylene oxide diol of between 800 and 5,000 MW, trimethylolpropane, and the low molecular weight polyisocyanate, and wherein at least 1% of said composition by weight, but not more than 5% of said composition by weight, comprises the low molecular weight polyisocyanate as a free polyisocyanate;

and wherein on average in the composition, 10% to 30% of the monomers of said block copolymer polyol are derived from propylene oxide monomers, and the rest of the monomers are ethylene oxide derived monomers;

characterized in that after polymerization, upon exposure to tissue or water, the adhesive composition forms a hydrogel comprising, after equilibration with water or aqueous fluids, greater than 50% water by volume; and

wherein the composition polymerizes in situ upon exposure to water and application to tissue, without requiring the addition of a catalyst.

- 2-6. (Cancelled).
- 7. (Previously Presented) The biocompatible composition as recited in claim 1 wherein said polyisocyanate comprises 2,6-toluene diisocyanate.
- 8. (Previously Presented) The biocompatible composition as recited in claim 1 wherein said polyisocyanate comprises isophorone diisocyanate.

- 9. (Previously Presented) The biocompatible composition as recited in claim 1 wherein said polyisocyanate comprises an 80:20 mixture of 2,4- toluene diisocyanate and 2,6-toluene diisocyanate.
- 10. (Previously Presented) The biocompatible composition as recited in claim 1 wherein said polyisocyanate comprises isophorone diisocyanate and about 1.5% of said composition is the free polyisocyanate.
- 11. (Previously Presented) The biocompatible composition as recited in claim 1, wherein said composition is comprised of toluene diisocyanate and isophorone diisocyanate and wherein toluene diisocyanate comprises a free isocyanate isophorone diisocyanate is used to endcap said copolymer.
  - 12-50. (Cancelled).
- 51. (Previously Presented) The biocompatible composition as recited in claim 1, further comprising:

an activating component, consisting essentially of water, optionally containing medically compatible water soluble or miscible materials, which is mixed with the liquid reactive component at the time of application to tissue.

- 52. (Previously Presented) The biocompatible composition as recited in claim 1, wherein each hydroxyl group of said polyol is terminated with the low molecular weight polyisocyanate without the use of a catalyst, the isocyanate group to hydroxyl group ratio being in the range of 1.5 to 3.0.
- 53. (Previously Presented) The biocompatible composition as recited in claim 9, wherein about 3% of the composition is free polyisocyanate.